head and neck cancer – Page 9

Germany’s Merck halts supply of cancer drug to Greek hospitals

Source: Reuters.com Date: November 3, 2012 German pharmaceuticals firm Merck KGaA is no longer delivering cancer drug Erbitux to Greek hospitals, a spokesman said on Saturday, the latest sign of how an economic and budget crisis is hurting frontline public services. Drugmakers raised concerns with EU leaders earlier this year over supplies to the euro zone's crisis-hit southern half and Germany's Biotest in June was the first to stop shipments to Greece because of unpaid bills. Publicly-owned hospitals in some countries worst hit by the euro zone debt crisis had been struggling to pay their bills, Merck's chief financial officer, Matthias Zachert, was quoted as saying by German paper Boersen-Zeitung in an interview on Saturday. He said however that the only country where Merck had stopped deliveries was Greece. "It only affects Greece, where we have been faced with many problems. It's just the one product," he told the paper. A spokesman for the company told Reuters that the drug concerned was Erbitux and that ordinary Greeks can still purchase it from pharmacies. Some countries have taken action to pay bills, such as in Spain, where the government has said it will help hospitals to pay off debts. "That has improved things, even though the situation should still be regarded as critical for the coming years," Zachert said. Erbitux is Merck's second best-selling prescription drug, bringing in sales of 855 million euros ($1.1 billion) in 2011 from treating bowel cancer and head and neck cancer. ($1 = 0.7785 euros) This news story was resourced by the Oral Cancer [...]

Charlotte Parker2012-11-05T11:16:35-07:00November, 2012|Oral Cancer News|

Studies question value of certain HNC biomarkers

Source: Dr.Biscuspid.com September 19, 2012 -- Human papillomavirus (HPV) DNA positivity alone, particularly when assessed using polymerase chain reaction methods, is a poor biomarker for HPV-driven head and neck cancers (HNCs), according to two studies published in Cancer Research (September 18, 2012). These studies identified alternative potential markers, including viral load, viral gene expression, and the evaluation of HPV DNA in combination with certain HPV assays. Prior research has established that HPV is a cause of some head and neck cancers, including oropharyngeal cancer, and that patients with HPV-associated disease tend to have a better clinical outcome. Consequently, the proper assessment of the clinical status of individual tumors has become a goal of clinicians treating this disease because HPV at the tumor site does not indicate causal involvement in the cancer. In the first study, Dana Holzinger, PhD, of the division of genome modifications and carcinogenesis at the German Cancer Research Center, and colleagues analyzed the potential of direct and indirect HPV markers to identify patients with HPV-driven tumors. They analyzed 199 oropharyngeal squamous cell carcinoma specimens for HPV DNA, viral load, RNA expression patterns seen in cervical carcinomas, and the p16 protein. They found that the cervical cancer RNA expression pattern and viral load were associated with the lowest risk for death from oropharyngeal cancer. In contrast, a weaker association was found for samples that were HPV DNA-positive or that expressed the p16 protein. "We showed that high viral load and a cancer-specific pattern of viral gene expression are [...]

Charlotte Parker2012-09-28T13:42:14-07:00September, 2012|Oral Cancer News|

CMC gets $8M to study oral damage from radiation

Source: wcnc.com by Karen Garloch / The Charlotte Observer A research team in the Department of Oral Medicine at Carolinas Medical Center has received an $8 million grant from the National Institutes of Health to study tissue damage in patients who have received high-dose radiation for head and neck cancer. Hospital officials said it is the largest research grant ever awarded to CMC. Dr. Michael Brennan, associate chairman of the oral medicine department, will be principal investigator for the Charlotte research site. Patients will also be enrolled at Harvard University, University of Pennsylvania, New York University and the University of Connecticut. Brennan said the five-year study will help doctors develop evidence-based guidelines for the care of patients’ dental health before or after radiation therapy. Patients with head and neck cancer often receive high-dose radiation therapy that results in lifelong damage to oral and facial tissues. Side effects include a decrease in saliva production, which increases the risk of tooth decay and tooth loss. Radiation can also impair bone healing, leading to an increased risk of infection around the teeth and increased risk of jaw fractures and pain that could require surgery. Patients enrolled in the study will receive a standard dental assessment prior to radiation therapy, and follow-up visits will be conducted every six months for up to two years. This news story was resourced by the Oral Cancer Foundation, and vetted for appropriateness and accuracy.

Charlotte Parker2012-09-28T09:39:10-07:00September, 2012|Oral Cancer News|

Robotic Surgery Through The Mouth Safe For Removing Tumors Of The Voice Box, Study Shows

Source: HealthCanal.com COLUMBUS, Ohio – Robotic surgery though the mouth is a safe and effective way to remove tumors of the throat and voice box, according to a study by head and neck cancer surgeons at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James). Dr. Enver Ozer This is the first report in the world literature illustrating the safety and efficacy of transoral robotic surgery for supraglottic laryngectomy, the researchers say. The preliminary study examined the outcomes of 13 head and neck cancer patients with tumors located in the region of the throat between the base of the tongue and just above the vocal cords, an area known as the supraglottic region. The study found that the use of robot-assisted surgery to remove these tumors through the mouth took about 25 minutes on average, and that blood loss was minimal – a little more than three teaspoons, or 15.4 milliliters, on average, per patient. No surgical complications were encountered and 11 of the 13 patients could accept an oral diet within 24 hours. If, on the other hand, these tumors are removed by performing open surgery on the neck, the operation can take around 4 hours to perform, require 7 to 10 days of hospitalization on average and require a tracheostomy tube and a stomach tube, the researchers say. The findings were published recently in the journal Head and Neck. “The transoral robotic technique means shorter [...]

Charlotte Parker2012-09-26T09:38:37-07:00September, 2012|Oral Cancer News|

Head and neck cancer rates for smokeless tobacco described

Source: Health News Observer September 16, 2012 | by Steven Rothrock MD Smokeless tobacco is tobacco that is not burned or smoked. Other terms used for smokeless tobacco include chewing tobacco, spitting tobacco, dip, chew, and snuff. Typically these products are held in the mouth until juices are built up and spit out. Spitless products are available and some people choose to swallow the juices instead. Nicotine, which can be addictive, and cancer-causing agents are absorbed through the mouth’s lining. While using smokeless tobacco has been associated with many different cancers, the magnitude of the risk has not been previously well described. This week, in an online edition of the International Journal of Cancer, researchers sought to identify the magnitude of the risk of developing head and neck cancer in those who used smokeless tobacco. Towards that goal, the risk of cancer was compared between 1,046 users and 1,239 non-users of smokeless tobacco. After adjusting for age, sex, race, education, cigarette smoking, and alcohol use, any use of smokeless tobacco was associated with a 20% increased risk of head and neck cancer. Use of smokeless tobacco for 10 or more years had a 320% higher rate of developing these cancers compared to those who never used these products. In addition to head and neck cancers, users of these products are at risk for other cancers (e.g. esophageal, pancreatic, kidney), heart disease, high blood pressure, pregnancy loss, premature birth or low birth weights, low sperm counts, not to mention tooth gum [...]

Charlotte Parker2012-09-18T13:50:57-07:00September, 2012|Oral Cancer News|

It Costs More, but Is It Worth More?

Source: The New York Times- Opinion Pages By EZEKIEL J. EMANUEL and STEVEN D. PEARSON If you want to know what is wrong with American health care today, exhibit A might be the two new proton beam treatment facilities the Mayo Clinic has begun building, one in Minnesota, the other in Arizona, at a cost of more than $180 million dollars each. They are part of a medical arms race for proton beam machines, which could cost taxpayers billions of dollars for a treatment that, in many cases, appears to be no better than cheaper alternatives. Proton beam therapy is a kind of radiation used to treat cancers. The particles are made of atomic nuclei rather than the usual X-rays, and theoretically can be focused more precisely on cancerous tissue, minimizing the danger to healthy tissue surrounding it. But the machines are tremendously expensive, requiring a particle accelerator encased in a football-field-size building with concrete walls. As a result, Medicare will pay around $50,000 for proton beam therapy for a patient with prostate cancer, roughly twice as much as it would if the patient received another type of radiation. The higher price would be worth it if proton beam therapy cured more people or significantly reduced side effects. But there is no evidence showing that this is true, except for a handful of rare pediatric cancers, like brain and spinal cord cancer. For children, the treatment does a better job of limiting damage to normal brain cells and reducing the [...]

Charlotte Parker2012-08-28T09:24:52-07:00August, 2012|Oral Cancer News|

Fewer teens having oral sex

Source: CNN.com Fewer teens aged 15 to 17 are having oral sex now than in 2002, according to a new report from the U.S. Centers for Disease Control, but the number remains high. The report, based on data from The National Survey of Family Growth, found that more than a third of teens had engaged in oral sex by the time they turned 17. That number climbed to almost 50% by age 19, and more than 80% for 24-year-olds. The study - based on computer surveys given to over 6,000 teens - also looked at the timing of first oral sex in relation to the timing of first vaginal intercourse. It found that the prevalence of having oral sex before vaginal intercourse was about the same as those having vaginal intercourse before oral sex. "This new CDC analysis debunks many myths about when young people are initiating oral sex," wrote Leslie Kantor, vice president for education at Planned Parenthood, a family planning advocacy group. "Although there has never been data to support it, there has been the perception that many teens engage in oral sex as a 'risk-free' alternative to intercourse. But the CDC analysis shows that sexually active young people are likely to engage in both activities," she wrote. How Americans view teen sex But oral sex, like vaginal intercourse, is not risk-free. According to the CDC's website, "numerous studies have demonstrated that oral sex can result in the transmission of HIV and other sexually transmitted disease," not the least of which [...]

Charlotte Parker2012-08-20T10:51:44-07:00August, 2012|Oral Cancer News|

New Guidelines for Head & Neck Cancer Reirradiation

Source: PhysciansWeekly.com Recurrent and second primary head-and-neck squamous cell carcinomas arising within or close to previously irradiated areas are a significant clinical challenge. The American College of Radiology published appropriateness criteria for recurrent head and neck cancer after prior definitive radiation. Recurrent and second primary head-and-neck squamous cell carcinomas (HNSCC) arising within or close to previously irradiated areas are a significant clinical challenge. Salvage surgical resection is the standard of care, but reirradiation is the only potentially curative treatment when surgery is not an option. Reirradiation is more challenging than initial treatment because of the side effects of prior therapy and concerns about the risks of high cumulative radiation doses to normal structures. Multi-institutional trials and large single institutional experiences have demonstrated that aggressive reirradiation, most often with chemotherapy, is feasible and provides durable locoregional control in some patients. An Expert Consensus on Reirradiation In the August 1, 2011 International Journal of Radiation Oncology * Biology * Physics, the American College of Radiology (ACR) published appropriateness criteria for recurrent head and neck cancer after prior definitive radiation. The ACR expert panel recommended that patient evaluation and reirradiation for HNSCC be performed at a tertiary care center with a head and neck oncology team that is equipped with the resources and experience to manage the complexities and toxicities of retreatment. Evaluation of Patients with Head & Neck Cancer Patient evaluation is important in assuring only appropriate patients are offered reirradiation. Evaluation should include careful restaging imaging, a detailed history and assessment [...]

Charlotte Parker2012-08-20T10:43:31-07:00August, 2012|Oral Cancer News|

Perspectives on Coping Among Patients With Head and Neck Cancer Receiving Radiation

Source: MedScape News Today Abstract and Introduction Abstract Purpose/Objectives: To describe coping among patients with laryngeal and oropharyngeal cancer during definitive radiation with or without chemotherapy. Research Approach: Qualitative content analysis conducted within a larger study. Setting: Two radiation oncology outpatient clinics in Baltimore, MD. Participants: 21 patients with oropharyngeal or laryngeal cancer. Methodologic Approach: Interviews with open-ended questions were conducted during treatment. Questions covered topics such as coping during treatment, treatment-related issues, and resources. Main Research Variables: Coping, treatment, and coping resources. Findings: Patients' self-assessments suggested they were coping or that coping was rough or upsetting. Issues that required coping varied over four time points. Physical side effects were problematic during and one month after treatment completion. Patients used coping to manage the uncertainties of physical and psychological aspects of their experience. Family and friend support was a common coping strategy used by patients, with the intensity of side effects corresponding with the support provided across time points. Conclusions: Findings confirm previous research, but also provide new information about ways in which patients with head and neck cancer cope with their illness experience. Emergent themes provide insight into patients' feelings, issues, and assistance received with coping. Interpretation: Patients with head and neck cancer need education on the amount and severity of side effects and should be appraised of potential difficulties with scheduling, driving, and other logistic issues. Patients also should be informed of helpful types of support and coping strategies. Additional research is needed to expand the findings related [...]

Charlotte Parker2012-06-27T10:08:59-07:00June, 2012|Oral Cancer News|

Penn study finds delayed side effects of head and neck cancer treatments go unreported

Source: Eurekalert.org Results reinforce need for improved 'survivorship care' to encourage patients to seek help for their symptoms CHICAGO – New data from an Internet-based study show that patients with head and neck cancers (HNC) may be at risk for significant late effects after their treatment, but they're unlikely to discuss these and other survivorship care issues with their doctors. The findings, from researchers at the Perelman School of Medicine at the University of Pennsylvania, will be presented Monday, June 4, at the 2012 American Society of Clinical Oncology (ASCO) meeting in Chicago. The research team says the study reinforces the need to improve survivorship care for patients as they complete their active treatment, better educate patients about late effects they may experience, and encourage them to report these problems to their healthcare providers so they can be addressed. Data from nearly 4,000 cancer survivors were gathered between April 2010 and October 2011 via patients who completed LIVESTRONG Care Plans via OncoLink, Penn Medicine's online cancer resource. Approximately four percent of those patients had been treated for a primary head or neck cancer. Of those, nearly 88 percent reported having undergone radiation, 73 percent surgery, and 67 percent chemotherapy. Many patients reported late effects such as difficulty swallowing/speaking (83 percent), decreased saliva production (88 percent), thyroid problems (33 percent), decreased neck mobility (60 percent), concerns regarding cognitive function (53 percent), or vision deficits. However, since results show that patients only discuss the survivorship care plans they created on the site [...]

Charlotte Parker2012-05-31T12:09:42-07:00May, 2012|Oral Cancer News|